At a glance
ClinicalIndex Comparison RecordN/ACompleted· 94 enrolled
Drug / intervention
Tandem t:slim X2 insulin pump with Control IQ technologydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Closed-loop Insulin Delivery by Glucose Responsive Computer Algorithms In Type 1 Diabetes Pregnancies (CIRCUIT)
In Brief
A clinical study evaluating Tandem t:slim X2 insulin pump with Control IQ technology for Type 1 Diabetes Mellitus and 4 related conditions. Completed, enrolled 94 participants across 14 sites in 2 countries.
Detailed Summary
This trial will assess the efficacy of the Tandem t:slim X2 insulin pump with Control IQ technology compared with standard insulin delivery plus CGM in pregnant women with type 1 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus, Pregnancy Related, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
CountriesAustralia, Canada
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJun 2021
Primary CompletionMay 2025
TodayJul 2026
First PostedMay 26, 2021
Enrollment StartJun 15, 2021
Primary CompletionMay 23, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.1 years ago
Interventions
Tandem t:slim X2 insulin pump with Control IQ technologydevice
The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.